ALT - Altimmune, Inc.

QQQ $ 454.82 $ 0.38 (0.08 %)

DIA $ 398.57 $ -2.42 (-0.62 %)

SPY $ 530.36 $ -1.44 (-0.27 %)

TLT $ 91.26 $ -0.47 (-0.5 %)

GLD $ 225.37 $ -0.32 (-0.15 %)

Previous Close

$ 7.38

Open

$ 7.42

Bid

$ 7.02 x 100

Ask

$ 7.05 x 253

Day's Range

$ 7.07 - $ 7.46

52 Week Range

$ 2.09 - $ 14.84

Volume

1,776,601

Average Volume

Market Cap

522.52M

Beta (5Y Monthly)

$ 0.10

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	03-27-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-15-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-10-2021	06-30-2021	10-Q
13	05-17-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-13-2020	03-31-2020	10-Q
18	03-27-2020	12-31-2019	10-K
19	11-13-2019	09-30-2019	10-Q
20	08-13-2019	06-30-2019	10-Q
21	05-14-2019	03-31-2019	10-Q
22	04-01-2019	12-31-2018	10-K
23	11-13-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q
25	05-15-2018	03-31-2018	10-Q
26	04-02-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-03-2017	03-31-2017	10-Q
30	03-14-2017	12-31-2016	10-K
31	11-04-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	03-11-2016	12-31-2015	10-K
35	11-06-2015	09-30-2015	10-Q
36	08-05-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	03-11-2015	12-31-2014	10-K
39	11-06-2014	09-30-2014	10-Q
40	08-05-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Altimmune Presents New Data on Pemvidutide...
06/05/2024 11:12:26

Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflam...

How Is The Market Feeling About Altimmune?
06/03/2024 13:00:20

HC Wainwright & Co. Reiterates Buy on Alti...
05/14/2024 11:51:33

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

JMP Securities Maintains Market Outperform...
05/10/2024 16:34:39

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price targ...

Altimmune Q1 2024 GAAP EPS $(0.34) Beats $...
05/09/2024 11:15:36

jim-cramer-calls-nutanix-the-perfect-enterprise-software-company-for-the-moment

Jim Cramer Calls Nutanix 'The Perfect Ente...
05/07/2024 12:33:34

Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money."

peering-into-altimmunes-recent-short-interest

Peering Into Altimmune's Recent Short Inte...
04/30/2024 13:30:15

Why Clever Leaves Holdings Shares Are Trad...
04/29/2024 17:04:01

deutsche-bank-daqo-new-energy-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Deutsche Bank, Daqo New Energy And Other B...
04/29/2024 12:31:09

Guggenheim Downgrades Altimmune to Neutral
04/29/2024 10:41:55

Guggenheim analyst Seamus Fernandez downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral.

How Is The Market Feeling About Altimmune?
04/08/2024 13:00:33

if-you-invested-100-in-this-stock-5-years-ago-you-would-have-300-today

If You Invested $100 In This Stock 5 Years...
04/03/2024 20:31:16

HC Wainwright & Co. Maintains Buy on Altim...
04/01/2024 16:23:36

HC Wainwright & Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target fro...

why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Kodiak Sciences Shares Are Trading Low...
03/28/2024 18:08:52

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

B. Riley Securities Reiterates Buy on Alti...
03/28/2024 15:56:51

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.

rex-american-resources-reports-upbeat-earnings-joins-avalo-therapeutics-rh-and-other-big-stocks-moving-higher-on-thursday

REX American Resources Reports Upbeat Earn...
03/28/2024 15:00:16

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...

why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday

Why Is Obesity Drug Developer Altimmune St...
03/27/2024 13:31:39

Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipos...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
03/27/2024 13:05:57

Altimmune Q4 GAAP EPS $(0.54) Misses $(0.4...
03/27/2024 11:04:47

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.43) by...

Altimmune Announces Lean Mass Preservation...
03/27/2024 11:03:07